EvoLiver, a blood test that detects early-stage liver cancer with high accuracy, has gained breakthrough device designation ...

Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer ... with the highest rates observed in East Asia.

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

Mursla Bio, a Cambridge UK and Boston US leader in Extracellular Vesicle (EV) science, has received FDA approval for its lead ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and ...

which is enabled by a novel platform based on organ-specific EVs for the surveillance of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, in high-risk cirrhotic patients.